Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3

Conditions

Carcinoma, Non-Small-Cell Lung 31Lung Neoplasms 14Neoplasms 10Thoracic Neoplasms 3Carcinoma 3Respiratory Tract Neoplasms 2Respiratory Tract Diseases 2Neoplasms, Nerve Tissue 2Neoplasms by Site 2Neoplasms by Histologic Type 2Neoplasm Metastasis 2NSCLC 2Meningeal Carcinomatosis 2Lung Diseases 2Colorectal Neoplasms 2Carcinoma, Bronchogenic 2Bronchial Neoplasms 2Brain Neoplasms 2Adenocarcinoma 2Solid Tumor, Adult 1Renal Insufficiency 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Noonan Syndrome 1Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) 1Multiple Endocrine Neoplasia Type 2a 1Mesothelioma, Malignant 1Lung Cancer Metastatic 1Lethal Congenital Contracture Syndrome 2 1Hemangioendothelioma, Epithelioid 1Head and Neck Neoplasms 1

Interventions

osimertinib 3entinostat 3Pemetrexed 2Carboplatin 2sotorasib 1pembrolizumab 1exemestane 1Tyrosine Kinase Inhibitors 1Sunitinib 1Indocyanine Green 1Erlotinib Hydrochloride 1Dasatinib 1Afatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Thoracic Neoplasms × osimertinib × Clear all
NCT04862780 2025-02-10

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
177 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT04959981 2023-07-25

HERKULES-2

Erasca, Inc.

Phase 1 Completed
24 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Noonan Syndrome, Thoracic Neoplasms

NCT05153408 2023-06-18

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Blueprint Medicines Corporation

Phase 1 Terminated
20 enrolled
Thoracic

Adenocarcinoma, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡